FDA Needs To Track Actions Built On Supplement AERs – GAO Report
This article was originally published in The Tan Sheet
Executive Summary
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.
You may also be interested in...
GMP Inspectors Will Scrutinize Adverse Event Reporting Compliance
Regular under-reporting of serious adverse event reports has spurred FDA to have its good manufacturing practice inspectors review dietary supplement firms’ AERs and reporting practices, FDA’s Fabricant says. Key compliance issues can tip off the agency that a company may be falling short on reporting.
Enforcement In Brief
GMP violations lead to prison time; Syntec supplements seized; FDA warns NanoLiposomal Nutritionals; and more Enforcement In Brief.
Durbin Bill Would Narrow Definition Of Dietary Supplement
Legislation Sen. Dick Durbin offers to stop firms from allegedly side-stepping food safety standards by labeling products as dietary supplements could have a "devastating impact on the industry," stakeholders say.